DAKO ApS

The main activity in Dako Aps hereinafter referred as “company” is to hold the shares in Dako Denmark Aps. The Dako Group continues to build its business on a legacy of more than 50 years within pathology: From playing a pioneering role in the standardization of antibodies to Dako’s current role as an Agilent Technologies company with a leading position in the pathology segment of the in vitro diagnostics (IVD) industry.

Dako’s products are sold in more than 110 countries around the world and dedicated employees work to develop, manufacture and market reagents, antibodies, instruments and software for use in anatomic pathology laboratories worldwide.

Financial Position for the year

Net Income for the year is DK 268,587. As of 31st October 2019, the company has an equity of DKK 6.2 Billion.

Future Expectations

The Agilent group is exploring a re-organization of its operations in Denmark in upcoming year(s), the company will also participate in this re-organizing exercise. On 1st April 2020, the Board of Directors intends to declare an extraordinary dividend of in-kind assets which it would in turn receive from Dako Denmark ApS as dividends.

Significant events after the end of the financial year

Apart from the abovementioned developments and planned distributions mentioned below, the Board of Directors and Executive Management are not aware of any event after 31st October 2019 that may have a material impact on the company’s financial position.

Joint liabilities The company is jointly and severally liable together with the parent company and the other group companies in the joint taxable group for tax on the group’s joint taxable income and for certain possible withholding taxes, such as dividend tax, etc.

Tax payable on the Group’s joint taxable income is stated in the annual report of Agilent Technologies Denmark ApS, which serves as management company for the joint taxation.

Charges and securities 7

None.